Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy Subjects

This analysis was conducted to characterize the pharmacokinetics and pharmacodynamics of pegfilgrastim and to develop a pharmacokinetic‐pharmacodynamic model to describe the granulopoietic effects of pegfilgrastim and the homeostatic regulation of pegfilgrastim clearance in healthy subjects. Pegfilgrastim serum concentration data and differential white cell counts were obtained from an open‐label, single‐dose, dose escalation study. Healthy subjects (8 subjects/dose group) received a single subcutaneous dose of 30, 60, 100, or 300 μg/kg pegfilgrastim. Pegfilgrastim exhibited nonlinear pharmacokinetics; clearance decreased with increasing dose. A dose‐dependent increase in absolute neutrophil count with an increase in the percentage of band cells was observed. A pharmacokinetic‐pharmacodynamic model was developed that adequately described the nonlinear pharmacokinetics of pegfilgrastim, feedback regulation of pegfilgrastim clearance by neutrophils, and the differential effects of pegfilgrastim on neutrophil populations in blood.

[1]  T. Dexter,et al.  Filgrastim (r-metHuG-CSF) in clinical practice , 1998 .

[2]  Mary Jy.  Normal human granulopoiesis revisited. I. Blood data. , 1984 .

[3]  J. Hogg,et al.  Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior. , 2000, The hematology journal : the official journal of the European Haematology Association.

[4]  J. Crawford,et al.  Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Bing Wang,et al.  Population Pharmacokinetic–Pharmacodynamic Modeling of Filgrastim (r-metHuG-CSF) in Healthy Volunteers , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[6]  R. Allen,et al.  Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. , 1994, Blood.

[7]  T. Chard,et al.  Pregnancy-specific beta-glycoprotein in complications of early pregnancy. , 1980, Lancet.

[8]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[9]  J. Gabrilove,et al.  Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.

[10]  D. Metcalf.  Cell–cell signalling in the regulation of blood cell formation and function , 1998, Immunology and cell biology.

[11]  G. Chatta,et al.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.

[12]  W P Sheridan,et al.  Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. , 1989, Blood.

[13]  R. Willemze,et al.  Neutrophil kinetics and the regulation of granulopoiesis. , 1980, Reviews of infectious diseases.

[14]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[16]  Thomas M. Ludden,et al.  Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  T. Ulich,et al.  Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. , 1988, The American journal of pathology.

[18]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[19]  R. Pettengell,et al.  Filgrastim Review of its Pharmacological Properties and Therapeutic Efficacy in Neutropenia , 1994 .

[20]  M. Kawagishi,et al.  Neutrophil kinetics of recombinant human granulocyte colony-stimulating factor-induced neutropenia in rats. , 1990, Life sciences.

[21]  B. Lord,et al.  Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Lawrence F. Shampine,et al.  Implementation of Rosenbrock Methods , 1982, TOMS.

[23]  L. Harker,et al.  Neutrophil kinetics in the dog. , 1975, The Journal of clinical investigation.

[24]  K. Zsebo,et al.  Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. , 1986, Immunobiology.

[25]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Roskos,et al.  Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. , 2004, Journal of pharmaceutical sciences.